Evidence map›Paper›PMID 41971167›Full record

ArticleBio-protocol2026

ELISA-Based Enzyme Kinetics Assay for Measuring cGAS Activity.

Cécile Fréreux, Philip H Howe

Abstract read
In one paragraph

Article in Bio-protocol, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Cécile FréreuxDepartment of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC, USA.
Philip H HoweDepartment of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cyclic GMP-AMP synthase (cGAS) is a key cytosolic double-stranded DNA sensor that activates innate immune responses. Upon binding double-stranded DNA, cGAS undergoes conformational activation and catalyzes the synthesis of the second messenger 2'3'-cyclic GMP-AMP (2'3'-cGAMP) from ATP and GTP. 2'3'-cGAMP then triggers a downstream signaling cascade that induces type-I interferon and inflammatory gene expression and has been shown to exert antitumor effects in the context of cancer. Accurate measurement of this enzymatic activity is therefore important for mechanistic studies. Traditional kinetic methods such as radiolabeling, HPLC, or mass spectrometry provide precise results but require specialized equipment and expertise. Here, we describe a rapid and accessible ELISA-based protocol to quantify 2'3'-cGAMP product formation and derive cGAS enzymatic parameters. Reactions are initiated with defined DNA ligands and quenched at multiple time points, and product accumulation is quantified by a commercially available 2'3'-cGAMP ELISA. Time course measurements are used to calculate initial velocities, which can be plotted against substrate concentration to obtain Michaelis-Menten parameters. This approach enables direct, product-specific quantification of 2'3'-cGAMP formation using only an absorbance plate reader. The protocol provides a sensitive and broadly applicable alternative to traditional methods, allowing laboratories without advanced instrumentation to perform reliable cGAS enzyme kinetics. Key features • Developed to evaluate how cofactors or regulatory proteins modulate cGAS activity in vitro. • Suitable for assessing cGAS kinetics with diverse nucleic acid substrates under defined reaction conditions. • Determination of initial (V

Indexed as

2′3′-cGAMP synthesisAccessiblecGASELISAEnzyme kineticsk1/2kcatMichaelis–MentenVmax

Identifiers

PMID41971167
PMCPMC13067154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.